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Summary Tumor angiogenesis is necessary for solid tumor progression and metastasis. Thus,
targeting tumor blood vessels is an important strategy for cancer therapy. Especially, it would give
large benefit to head and neck cancer patients if ideal anti-angiogenic drug is developed. Tumor
blood vessels have been shown to differ from their normal counterparts, for example, by changes
in morphology. An important concept in tumor angiogenesis is that tumor endothelial cells are
assumed to be genetically normal, even though these endothelial cells are structurally and
functionally abnormal. To date, many anti-angiogenic drugs have been developed, but it has been
also reported to cause toxic side effects. To develop ideal anti-angiogenic therapies, under-
standing tumor endothelial cell abnormalities is important. We have isolated tumor endothelial
cells from mouse tumor xenografts and have shown that tumor endothelial cells are abnormal.
Tumor endothelial cells upregulate many genes, such as epidermal growth factor receptor. Tumor
endothelial cells are also more sensitive to EGF. Unexpectedly, tumor endothelial cells were
cytogenetically abnormal. In marked contrast, freshly isolated normal endothelial cells were
diploid. We conclude that tumor endothelial cells can acquire cytogenetic abnormalities while in
the tumor microenvironment.
Here, we provide an overview of the current studies on tumor endothelial cell abnormalities.
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Angiogenesis, the process of new blood vessel growth, is
necessary for tumor progression and metastasis. Tumor blood
vessels provide nutrition and oxygen, and get rid of waste
from tumor tissue, resulting in tumor progression. Tumor
vessels act as gatekeepers for tumor cells to metastasize
to distant organs [1,2].
Thus, the attempt to target tumor endothelial cells with
angiogenic inhibitors (anti-angiogenic therapy) has been an
important strategy for cancer therapy, and many anti-angio-
genic drugs have been discovered and tested to date [3].
A traditional concept in anti-angiogenic therapy has been
that (i) one tumor endothelial cell supports many tumor cells.
Thus, to target endothelial cells may be a much more effec-
tive strategy than targeting tumor cells. (ii) Tumor endothe-
lial cells are the same among all tumor types. Hence, an ideal
anti-angiogenic drug could be useful in treating all cancers.
(iii) Tumor endothelial cells have been believed to be geneti-
cally stable until recently, so tumor endothelial cells may not
acquire drug resistance unlike tumor cells (Fig. 1). However,
recent studies suggest that tumor endothelial cells may be
different from normal endothelial cells and also may also be
heterogeneous among organs or tumor types. Contrary to the
presumption that anti-angiogenic drugs are not as toxic as
cytotoxic drugs, they are reported to cause severe side
effects such as lethal hemoptysis [4,5] and perforation of
intestines [6,7].
To develop ideal tumor anti-angiogenic therapies, under-
standing the biology of tumor endothelial cells is very impor-
tant.
2. Phenotype of tumor blood vessels
It is well documented that tumor blood vessels differ mor-
phologically from normal blood vessels (Fig. 2). Tumor vessels
are unorganized whereas the normal vasculature shows a
hierarchal branching pattern of arteries, veins and capillaries
[8]. Tumor endothelial cells do not form regular monolayers
and thus do not have a normal barrier function [9]. Tumor
endothelial cell basement membranes have structural
abnormalities including loose associations with endothelial
cells, and varied thicknesses of type IV collagen layers that
are usually not seen in normal endothelial cells [10]. Peri-
cytes are present on tumor endothelial cells, but have
abnormally loose associations with these cells and extend
cytoplasmic processes deep into the tumor tissue [11]. These
abnormalities result in leakiness of tumor blood vessels. In
addition, tumor blood vessels are often tortuous in appear-
ance with uneven vessel diameters due in part to compres-
sion of the immature vessel wall by tumor cells. Tumor vessels
exhibit chaotic blood flow and vessel leakiness due to looseendothelial cell interconnections [12]. The high interstitial
fluid pressure (IFP) in a tumor causes blood vessel collapse
and impedes blood flow. This is one reason why tumor tissue is
usually under the hypoxic condition, even though it is highly
vascularized. This sometimes causes resistance to radiation
therapy [13].
3. Differences between tumor endothelial
cells and normal endothelial cells
The morphological abnormalities in tumor blood vessels
compared to normal blood vessels raises questions as to
whether there are phenotypical differences at the molecular
and functional levels between tumor and normal endothelial
cells. To address this question, tumor endothelial cells iso-
lated from tumor tissue were required. However, there have
not been many reports about isolation of tumor endothelial
cells until recently. In fact, most studies on tumor angiogen-
esis have been done using normal endothelial cells such as
human umbilical vein endothelial cells (HUVEC), human
dermal microvascular endothelial cells (HMVEC) for a long
time. To isolate tumor endothelial cells for global analysis of
gene expression has been difficult because, (i) endothelial
cells are usually enmeshed in a complex tissue consisting of
vessel wall components, stromal cells, tumor cells; (ii) only a
small fraction of cells within these tissues are endothelial
cells. Besides technical difficulties, there might have been a
concern about trials to isolate tumor endothelial cells them-
selves, because they were sometimes considered to lose their
specific phenotype soon after being isolated from tumor
tissue. In the first report about tumor endothelial specific
markers, St. Croix et al. succeeded in isolating endothelial
cells from colon carcinoma and normal colonic mucosa and
compared the gene expression profiles between tumor and
normal endothelial cells of a relatively low number of cells.
They identified the specific genes for tumor endothelial cells
and designated them as tumor endothelial markers (TEMs)
using serial analysis of gene expression (SAGE). SAGE
revealed there are 46 tumor endothelial markers, called
TEMs [14]. Some of them are transmembrane proteins and
are also conserved in mice [15,16]. Very recently, they
showed that these TEMs, except TEM8, are also overex-
pressed during physiological angiogenesis, as well as in tumor
endothelial cells. Instead, they identified 13 novel cell sur-
face proteins as tumor endothelial markers [17]. Other stu-
dies about the gene profile of tumor endothelial using global
analysis have been published recently. Buckanovich et al.
identified 12 ovarian tumor vascular markers (TVMs) from
vascular cells captured by laser-capture microdissection
(LCM) and some TVMs correlated with the prognosis of
patients. However, they commented that these markers
are not strictly specific to tumor endothelial cells, because
Figure 1 The traditional belief of anti-angiogenic therapy. It has been believed that anti-angiogenic therapy has several advantages
traditionally. (1) To target endothelial cells may be a much more effective strategy than targeting tumor cells. (2) Tumor endothelial
cells are the same among all tumor types. Thus, an ideal anti-angiogenic drug could be useful in treating all cancers. (3) Tumor
endothelial cells were believed to be genetically stable until recently. Thus tumor endothelial cells may not acquire drug resistance,
unlike tumor cells (modified from Hida et al., Cancer sci vol. 99 no. 3 Fig. 1).
28 K. Hida et al.LCM-captured cells contain not only endothelial cells but also
mural cells such as pericytes or smooth muscle cells [18].
Ovarian tumor endothelial cells were also isolated with
magnetic beads and 23 tumor endothelial markers were
identified by DNA microarray [19]. Among the 23 markers,
several genes are involved in the proangiogenic pathway.
Colon carcinoma endothelial cell markers were also identi-
fied by SAGE [20,17].
However, tumor endothelial cells were not cultured in
these studies and the biological phenotype in tumor endothe-
lial cells remains to be clarified. Another study is based on
cultured tumor endothelial cells. For example, human renal
cell carcinoma endothelial cells did not undergo the senes-
cence that is typical of normal endothelial cells, and wereFigure 2 The differences in blood vessels between tumor and n
endothelial cell basement membranes have structural abnormalities
thicknesses of type IV collagen layers that are usually not seen in norm
with endothelial cells and extend cytoplasmic processes deep into
capillary—venule hierarchy. Tumor vessels exhibit chaotic blood flowresistant to apoptotic stimuli such as serum-starvation and
vincristine. They exhibited higher proliferation rates in low
serum, enhanced Akt activation, and decreased expression of
the tumor suppressor, PTEN [21]. Murine Lewis lung carci-
noma endothelial cells were characterized by elongated
morphology, and upregulated adhesion molecules such as
CD31 or ICAM-1. They required a tumor-specific matrix to
maintain their characteristics. Sca-1 expression was also
elevated in these cells suggesting the presence of circulating
endothelial progenitors (CEP) in their tumor endothelial cells
[22]. We have also purified tumor endothelial cells in an
attempt to better understand the effects of the tumor micro-
environment on endothelial cell properties [23]. Human tumor
xenograft models in nude mice were established as sources oformal tissues. Tumor vessels have excessive branching. Tumor
including loose associations with endothelial cells, and various
al endothelial cells. Pericytes have abnormally loose associations
the tumor tissue. Tumor vasculature shows lack of arteriole—
(modified from Hida et al., Cancer sci vol. 99 no. 3 Fig. 2).
Figure 3 Tumor endothelial cells differ from normal endothelial cells. (a) Tumor endothelial cells overexpress specific genes, such as
TEMs and EGFR. (b) They proliferate more rapidly and (c) are sensitive to growth factors such as bFGF, EGF and VEGF, or some drugs like
EGFR inhibitors. (d) Tumor EC are resistant to apoptotic stimuli such as serum starvation or chemotherapeutic drug and (e) have
cytogenetical abnormalities. (f) There are some EPC-derived endothelial cells in tumor vessels (modified from Hida et al., Cancer sci
vol. 99 no. 3 Fig. 2).
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liposarcoma) endothelial cells and normal (skin and adipose)
endothelial cell counterparts were isolatedwith high purity by
combination with magnetic bead cell sorting [24]. Since it is
known that heparin binding EGF like growth factor (HB-EGF) is
a receptor of diphtheria toxin (DT) in human cells, but not
mouse cells, and DT binds to human cells expressing HB-EGF
and is toxic to themwhile mouse cells are resistant to DT [25],
we used DT in tumor endothelial cell isolation [24]. To remove
any human tumor cell contamination which might have over-
grown in the endothelial cell culture, DT was added to the
tumor endothelial cell subculture to kill human cells and
normal endothelial cells for technical consistency. The mouse
tumor endothelial cells expressed typical endothelial cell
markers suchasCD31, VEGF receptors andupregulated several
tumor endothelial markers which have already been reported,
such as TEMs [24] or Aminopeptidase N (CD13) (data not
published). From these data, tumor endothelial cells retain
their specificity for tumor endothelial cells (at least some)
even in culture. Tumor endothelial cells grew faster, had a
lower serum requirement, andweremore responsive to angio-
genic growth factors such as basic fibroblast growth factor
(bFGF) and vascular endothelial growth factor (VEGF) com-
pared to normal counterpart endothelial cells [23]. Further-
more,we have found that tumor endothelial cells express high
levels of EGFR, which is not usually expressed in normal
endothelial cells, such as HUVEC [26]. EGF can induce phos-
phorylation of tumor endothelial cell EGFR and stimulate
tumor endothelial cell proliferation. EGFR tyrosine kinase
inhibitors inhibit EGF-induced EGFR activation and prolifera-
tion of tumor endothelial cells. Thus, it was suggested that
EGFRkinase inhibitorsmay targetnotonly tumor cells, butalso
tumor endothelial cell EGFR. This data has clinical signifi-
cance. Anti-EGFR therapy could target tumor vasculature
specifically. Moreover, this therapy can be applied to any
cancer in which tumor cells do not express, or express a low
level of EGFR.
Taking the in vivo and in vitro studies together, there are
mounting evidences that there is distinct differences
between tumor and normal blood vessels and their endothe-
lial cells in terms of biology, morphology and gene profile
(Fig. 3).4. Cytogenetical abnormalities in tumor
endothelial cellsTumor endothelial cells had relatively larger nuclei, indicat-
ing they had more DNA content than normal endothelial cells
[24]. Strikingly, tumor endothelial cells were cytogenetically
abnormal. Tumor endothelial cells were karyotypically aneu-
ploid, whereas normal endothelial cells grown under the
same conditions were diploid. In addition, they had structural
aberrations such as non-reciprocal translocations, missing
chromosomes, marker chromosomes, and double minutes
by multiple colored fluorescent in situ hybridization (M-FISH)
analysis [24]. Thus, tumor endothelial cells have hallmarks of
chromosomal instability. To avoid possible artifacts due to
culture conditions, freshly isolated, uncultured endothelial
cells were analyzed by FISH. CD31 staining was used to
confirm endothelial cell identity. About 16% of liposarcoma
endothelial cells and 34% of melanoma endothelial cells were
aneuploid by FISH using a mouse chromosome 17 probe [24].
After this report, we recently investigated the aneuploidy of
other types of tumor endothelial cells. About 35% of oral
carcinoma endothelial cells (Fig. 4A) and 54% of renal carci-
noma endothelial cells (Fig. 4B) were also aneuploid even
when uncultured. Significantly, the degree of aneuploidy of
tumor endothelial cells almost doubled in culture in each
tumor endothelial cell. On the other hand, freshly isolated,
uncultured skin endothelial cells were diploid and remained
diploid when cultured (Fig. 4C). These results suggest that
tumor endothelial cells, unlike normal endothelial cells, have
chromosomal instability.
Aneuploid tumor endothelial cells were also detected on
frozen tumor sections by FISH. Tumor endothelial cells also
have abnormal centrosomes.
Since tumor endothelial cells continue to proliferate in
culture, it appears that these cells, like tumor cells, lack the
normal cell cycle checkpoints that inhibit mitosis in response
to chromosomal abnormalities. Recently, we found that
tumor endothelial cells have aneuploidy in also human renal
cell carcinomas as well as mouse tumor endothelial cells [27].
There are some other reports about chromosomal abnorm-
alities in tumor endothelial cells in hematopoietic tumors
Figure 4 The cytogenetically abnormal tumor endothelial cells. Mouse oral carcinoma endothelial cells (A) and renal carcinoma
endothelial cells (B) were isolated and cytospun onto glass slides, followed by immunostaining with an anti-CD31antibody and FISH with
a chromosome 17 probe. Representative aneuploid endothelial cells are shown. Normal endothelial cells (skin endothelial cells) are
diploid (C). Green; CD31, Red; chromosome 17, Blue; Dapi, Bar; 10 mm (modified from Hida et al., Cancer sci vol. 99 no. 3 Fig. 4). (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)
30 K. Hida et al.such as leukemia [28] and lymphoma [29]. In chronic myeloid
leukemia, for example, circulating endothelial cells had
leukemia-specific translocations [28]. In B-cell lymphomas,
37% of endothelial cells were shown to harbor lymphoma-
specific chromosomal translocations, suggesting that lym-
phoma and lymphoma endothelial cells may both be derived
from hemangioblastic cells [29]. In addition, circulating
endothelial cells in multiple myeloma had the same translo-
cation as myeloma cells, indicating the possibility that both
cells were originally from the same multipotent hemangio-
blast [30].
Furthermore, a recent study reported that neuroblastoma
endothelial cells had a varying proportion of microvascular
endothelial cells that exhibited MYCN amplification, which
are typically amplified in neuroblastoma, suggesting these
tumor endothelial cells are dedifferentiated from their
tumor origin [31].
5. Significance of tumor endothelial cell
aneuploidy
An abnormal chromosome number, aneuploidy, is a common
characteristic of tumor cells. In addition, it has been pro-
posed that aneuploidy cause tumorigenesis for nearly 100
years. However, this remains unproven since there have been
controversial reports that aneuploidy is merely a benign sideeffect of transformation or a contributor to tumor progres-
sion, but not to tumor initiation [32]. Recently, Weaver et al.
generated aneuploid cells and animals by reduction of Cen-
tromere-associated Protein-E (CENP-E). In their study, aneu-
ploidy was shown to promote spontaneous tumorigenesis in
aged animals, but at a modest frequency. However, an
increased rate of aneuploidy was shown to inhibit tumorigen-
esis [33].
To return to the subject of tumor endothelial cells, do
aneuploid tumor endothelial cells have tumorigenesity? Mel-
anoma and liposarcoma endothelial cells were plated in soft
agar to monitor anchorage-independent growth. However,
these tumor endothelial cells did not form colonies in soft
agar, whereas a mouse endothelial cell line (MS1) immorta-
lized by an SV40 Tantigen, formed colonies in soft agar. When
injected into nude mice subcutaneously, tumor endothelial
cells did not form tumors in mice, while MS1 cells did form
hemangioma in mice, consistently to previous report [34]
(data not shown). These data are still preliminary and many
further studies should be done before concluding that aneu-
ploid tumor endothelial cells are transformed or tumori-
genic.
In any case, the aneuploidy of tumor endothelial cells is
significant.Tumorendothelial cells havebeen considered tobe
genetically normal, unlike tumor cells, for a long time. How-
ever, aneuploid tumor endothelial cells may be a different
matter. Tumor endothelial cells may develop drug resistance
Significance of anti-angiogenic therapy in head and neck cancer–—Heterogeneity of tumor endothelium 31like tumor cells, contrary to past beliefs. It has been shown
previously that tumor endothelial cells in culture are more
resistant to vincristine than normal endothelial cells [21]. Our
studies also showed tumor endothelial cells were more resis-
tant to 5-FU than normal endothelial cells (unpublished data).
Some anti-angiogenic drugs have been shown to lose their
effectiveness over time, possibly due to acquired resistance.
For example, as amechanism of resistance to anti-angiogenic
therapy, it was suggested that survival factors such as cyto-
kines or growth factors which are rich in the tumor micro-
environment, may cause epigenetic changes not only in
tumor cells, but also in tumor endothelial cells [35]. For
example, bFGF was reported to inhibit apoptosis signal
kinase 1 (ASK1) activity, inducing chemoresistance in HUVEC
[36].
Taken together, the possibility that aneuploid tumor
endothelial cells are chemotherapy-resistant (or sensitive
to some drugs) warrants further investigation.
6. Conclusion
As reviewed in this article, tumor endothelial cells are
different from normal endothelial cells in gene profile and
behavior, besides the morphological changes described pre-
viously. Furthermore, the endothelial cells even in non-
hematopoietic solid tumors also have cytogenetic abnorm-
alities, contrary to the assumption that endothelial cells in
tumors are genetically stable and thus not drug-resistant. It is
speculated that drug resistance could possibly develop and
compromise the effectiveness of anti-angiogenic therapies.
Whatever mechanism underlies tumor endothelial abnorm-
ality, it is important to understand even stroma cells can be
abnormal in the tumor microenvironment. Recent studies
suggest that both tumor cells and cells in the tumor micro-
environment are a target for cancer therapy. Studies on
tumor endothelial cell abnormalities will help to develop
ideal anti-angiogenic therapies and also to understand how
tumor tissues are orchestrated by various cell types.
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